Skip to main content
Clinical Trials/JPRN-UMIN000028945
JPRN-UMIN000028945
Not yet recruiting
Phase 2

Multicenter phase II trial to evaluate the efficacy of Abound (nutrition product including HMB, arginine, and glutamine) on the clinical course of anastomotic leakage after gastrectomy in patients with gastric cancer - Efficacy of Abound on the clinical course of anastomotic leakage after gastrectomy in patients with gastric cancer

agoya University0 sites20 target enrollmentNovember 1, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Anastomotic leakage after gastrectomy for gastric cancer
Sponsor
agoya University
Enrollment
20
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 1, 2017
End Date
June 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agoya University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Severe pneumonia and sepsis 2\) Leakage at the closed stump of duodenum and jejunum 3\) Repeated surgery 4\) Patients requiring a limiting of the water amount 5\) Patients who underwent preoperative chemotherapy 6\) Patients incompatible to Abound 7\) Pregnancy 8\) Ineligible for the study at the physician's assessment.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A clinical trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer. PANGEA-Breast”Patients with HER2-negative advanced breast cancer.MedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-001779-54-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)36
Completed
Not Applicable
The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responsesCarcinoma of unknown primary origin (CUP)Cancer
ISRCTN17282276HS Greater Glasgow and Clyde (UK)59
Completed
Phase 2
Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancercolorectal cancer
JPRN-UMIN000027887ational Cancer Center Hospital East30
Recruiting
Phase 2
A multicenter phase II study to evaluate the efficacy and safety of fixed-duration sequential treatment combined with novel agents and autologous stem cell transplantation for newly diagnosed elderly multiple myeloma. -JSCT EMM21
JPRN-jRCTs071210084Kikushige Yoshikane75
Completed
Phase 2
A multicenter phase II trial of the efficacy and safety of tadalafil with pre-eclampsia.pregnancy induced hypertension
JPRN-UMIN000024042Mie university hospital, Department of Obstetrics and Gynecology160